36.90 -0.04 (-0.11%)
Pre-Market: 8:02AM EST
|Bid||36.83 x 700|
|Ask||36.98 x 900|
|Day's Range||36.50 - 37.28|
|52 Week Range||30.90 - 37.37|
|PE Ratio (TTM)||22.82|
|Forward Dividend & Yield||1.36 (3.68%)|
|1y Target Est||N/A|
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
Wall Street is already off to a hot start in the New Year, with the Dow surging to new heights and tech giants like Amazon.com, Inc. (NASDAQ:AMZN) and Nvidia Corporation (NASDAQ:NVDA) picking up right where they left off. The term “institutional investor” covers a large spectrum of companies and firms, including mutual and pension funds, endowments, private foundations, insurance companies, large investment firms, and more. Investment institutions, which pour hundreds of millions of dollars into different stocks, often employ teams of analysts that perform expensive and highly detailed research before making large stock purchases.
A Cambridge startup led by former executives at Pfizer and Biogen has attracted $58 million in financing as it seeks to pioneer a new class of drugs that can tweak the immune system without triggering major side effects. Pandion Therapeutics announced the Series A round on Thursday along with the appointments of Anthony Coyle as CEO and Jo Viney as chief scientific officer. Coyle previously led Pfizer’s (PFE) Centers for Therapeutic Innovation, a research and development group with offices in Cambridge, New York and California, while Viney led Biogen’s (BIIB) immunology research unit.
The Zacks Analyst Blog Highlights: Pfizer, Chevron, Cisco, Las Vegas Sands and Dominion Resources